Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Pharmaceuticals Industry
Nov 21, 2008 04:22 PM
- Notable Earnings After Market Close (10/22/2008) - Part 2
Oct 22, 2008 10:26 AM
- Analyst Comments: AGIX, Scientific Games, Sohu.com, Barclays, COSI, Cleveland-Cliffs,Potash Corp, Freddie Mac, OSI Pharma
Oct 08, 2008 08:44 AM
- Institutional Money Flocking in Biotech
Aug 15, 2008 01:23 PM
- Weekly Wrap + Market Forecast: SPX, Nasdaq, XLF, USO, GLD, FXI, BTK
Aug 04, 2008 01:56 AM
- Periodicals Wrap-Up for Thursday, July 31st
Jul 31, 2008 10:01 AM
- Biotechs Jump On IMCL
Jul 31, 2008 03:12 AM
- Keep An Eye on XLF, XHB, XLY and XLE for Rally Strength
Jul 21, 2008 02:07 PM
- Biotechs Jump While Energy Stocks Slump
Jul 16, 2008 02:10 AM
- Periodicals Wrap-Up for Friday, June 27th
Jun 27, 2008 10:32 AM
- Tarceva® (erlotinib) Endorsed by the U.K.’s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Nov 26, 2008 07:39 AM
- OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday,
December 4th
Nov 24, 2008 11:02 AM
- OSI Pharmaceuticals to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Nov 20, 2008 11:02 AM
- OSI Pharmaceuticals to Present at the Lazard Annual Healthcare Conference on Tuesday, November 18, 2008
Nov 11, 2008 11:04 AM
- Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
Nov 07, 2008 01:31 AM
- OSI Pharmaceuticals Announces Third Quarter 2008 Financial Results
Oct 22, 2008 04:12 PM
- OSI Pharmaceuticals to Announce Third Quarter Financial Results on October 22, 2008
Oct 10, 2008 10:02 AM
- Zacks Analyst Blog Highlights: The Potash Corporation of Saskatchewan, Inc., Freddie Mac, Fannie Mae, OSI Pharmaceuticals, Inc. And Stoneridge, Inc.
Oct 09, 2008 12:19 AM
- Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Oct 06, 2008 01:30 AM
- OSI Pharmaceuticals Announces Conversion Period for Convertible Notes
Oct 01, 2008 01:32 PM
- Form 4/A ATIEH MICHAEL G For: Nov 19 (10K)
Nov 25, 2008 04:28 PM
- Form 4 ATIEH MICHAEL G For: Nov 19 (10K)
Nov 21, 2008 12:18 PM
- Form 4 WHITE JOHN P For: Nov 17 (10K)
Nov 18, 2008 04:09 PM
- Form 4 OSI PHARMACEUTICALS INC For: Nov 07 Filed by: SIMON ROBERT L (10K)
Nov 12, 2008 10:43 AM
- Form 4 OSI PHARMACEUTICALS INC For: Oct 15 Filed by: WHITE JOHN P (10K)
Oct 16, 2008 04:24 PM
- Form 4 WHITE JOHN P For: Sep 15 (10K)
Sep 16, 2008 05:36 PM
- Form 4 OSI PHARMACEUTICALS INC For: Sep 02 Filed by: SIMON ROBERT L (10K)
Sep 04, 2008 04:13 PM
- Form 4 OSI PHARMACEUTICALS INC For: Sep 02 Filed by: GRANNER DARYL K (10K)
Sep 04, 2008 04:09 PM
- Form 4/A OSI PHARMACEUTICALS INC For: Aug 01 Filed by: GRANNER DARYL K (10K)
Aug 12, 2008 03:22 PM
- Form 4 OSI PHARMACEUTICALS INC For: Aug 01 Filed by: SIMON ROBERT L (10K)
Aug 05, 2008 01:12 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
OSIP
|
Compare to S&P
|
| YTD |
-27.33 %
|
-0.01 %
|
| 4 Weeks |
-4.70 %
|
12.92 %
|
| 12 Weeks |
-24.39 %
|
9.08 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -8.20 %
|
|
EPS Growth in Last Year: -15.15 %
|
|
Sales Growth in Last Quarter: -1.13 %
|
|
Sales Growth in Last Quarter: -5.78 %
|
|
|
